What is Leerink Partnrs’ Forecast for KYMR FY2024 Earnings?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of Kymera Therapeutics in a research report issued to clients and investors on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings per share of ($3.04) for the year, up from their prior estimate of ($3.25). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.85) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q4 2024 earnings at ($0.94) EPS, Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.18) EPS and FY2026 earnings at ($4.13) EPS.

Several other equities research analysts have also recently issued reports on the stock. Wolfe Research upgraded shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research report on Monday, August 26th. Leerink Partners reissued an “outperform” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Oppenheimer raised their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th. Truist Financial reissued a “buy” rating and issued a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a report on Friday. Finally, UBS Group cut their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $50.93.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $47.07 on Monday. The stock has a market cap of $2.91 billion, a P/E ratio of -20.12 and a beta of 2.21. Kymera Therapeutics has a 1 year low of $13.85 and a 1 year high of $53.27. The firm’s 50 day moving average price is $46.98 and its 200-day moving average price is $40.83.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The firm had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 28.05%. The company’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.90) earnings per share.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. raised its holdings in shares of Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after acquiring an additional 295 shares in the last quarter. Comerica Bank raised its holdings in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after acquiring an additional 400 shares in the last quarter. Keudell Morrison Wealth Management raised its holdings in shares of Kymera Therapeutics by 7.2% in the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock valued at $212,000 after acquiring an additional 480 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Kymera Therapeutics by 4.7% in the first quarter. Principal Financial Group Inc. now owns 12,098 shares of the company’s stock valued at $486,000 after acquiring an additional 547 shares in the last quarter.

Insiders Place Their Bets

In other news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.